Rifaximin Reduces Encephalopathy Recurrence, Improves Quality of Life in People with Liver Cirrhosis
- Details
- Category: Decompensation & ESLD
- Published on Friday, 28 May 2010 20:23
- Written by Liz Highleyman
The broad-spectrum antibiotic rifaximin (Xifaxan) improves quality of life for people with liver cirrhosis who experience recurrent episodes of hepatic encephalopathy, or brain disease, according to research presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Another analysis from the same study indicated that rifaximin works by lowering the level of ammonia in the blood.
More Articles...
- EASL 2010: HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin
- Chronic Hepatitis C Complications are Increasing, Especially among People Older than 60 Years
- Antibiotic Rifaximin Maintains Remission of Hepatic Encephalopathy in People with Advanced Liver Disease
- CROI 2010: Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
- Liver Transplant Do Not Impair Immune Response in HIV/HCV Coinfected Patients
Web Design and Development by